Business Segments · Product revenues, net
Reportable Segment — Product revenues, net
Insmed Reportable Segment — Product revenues, net increased by 16.0% to $305.96M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 229.6%, from $92.82M to $305.96M. Over 3 years (FY 2022 to FY 2025), Reportable Segment — Product revenues, net shows an upward trend with a 35.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2022
Last reportedQ1 2026
Rolls up toTotal Revenue
How to read this metric
An increase indicates growing market penetration and demand for the company's therapies.
Detailed definition
This represents the total revenue generated from the sale of commercial products after accounting for returns, allowance...
Peer comparison
Standard across all biopharmaceutical companies as the top-line revenue metric.
Metric ID:
insm_segment_reportable_segment_product_revenues_netHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $61.34M | $61.34M | $61.34M | $61.34M | $76.30M | $76.30M | $76.30M | $76.30M | $75.50M | $90.34M | $93.43M | $104.44M | $92.82M | $107.42M | $142.34M | $263.84M | $305.96M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +24.4% | +0.0% | +0.0% | +0.0% | -1.1% | +19.7% | +3.4% | +11.8% | -11.1% | +15.7% | +32.5% | +85.4% | +16.0% |
| YoY Change | — | — | — | — | +24.4% | +24.4% | +24.4% | +24.4% | -1.1% | +18.4% | +22.4% | +36.9% | +22.9% | +18.9% | +52.4% | +152.6% | +229.6% |
Range$61.34M – $305.96M
CAGR+49.4%
Avg YoY Growth+50.1%
Median YoY Growth+24.4%
Current Streak4 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Insmed's reportable segment — product revenues, net?
- Insmed (INSM) reported reportable segment — product revenues, net of $305.96M in Q1 2026.
- How has Insmed's reportable segment — product revenues, net changed year-over-year?
- Insmed's reportable segment — product revenues, net increased by 229.6% year-over-year, from $92.82M to $305.96M.
- What is the long-term trend for Insmed's reportable segment — product revenues, net?
- Over 3 years (2022 to 2025), Insmed's reportable segment — product revenues, net has grown at a 35.2% compound annual growth rate (CAGR), from $245.36M to $606.42M.
- What does reportable segment — product revenues, net mean?
- The total net sales generated from the company's commercialized pharmaceutical products.